pharma · Malaria · Pharmacokinetics · CNSP
CNS Pharmaceuticals
CNS Pharmaceuticals clinical programs — 9 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Houston, TX 77027, US
- Founded
- 2017
- Employees
- 12
- Programs
- 21
- Drugs
- 18
- Patents
- 0
CNS Pharmaceuticals projects
9 ClinicalTrials.gov programs sponsored by CNS Pharmaceuticals.
CNS Pharmaceuticals has 9 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
(+)-SJ000557733
CNS Pharmaceuticals
Plasmodium Falciparum Malaria
1 trial -
480 mg Piperaquine phosphate
CNS Pharmaceuticals
Malaria
1 trial -
ALPN-101
CNS Pharmaceuticals
Healthy Volunteers
1 trial -
Administration of the malaria inoculum
CNS Pharmaceuticals
Malaria
1 trial -
DAB
CNS Pharmaceuticals
Pharmacokinetics
1 trial -
Intravenous Vitamin C
CNS Pharmaceuticals
Pancreatic Cancer
1 trial -
MMV390048 40 mg
CNS Pharmaceuticals
Malaria
1 trial -
PRA
CNS Pharmaceuticals
Pharmacokinetics
1 trial -
SPR206
CNS Pharmaceuticals
Healthy Volunteers
1 trial
Frequently asked questions
How many clinical projects does CNS Pharmaceuticals have?
9 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.